<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05025527</url>
  </required_header>
  <id_info>
    <org_study_id>2021076</org_study_id>
    <nct_id>NCT05025527</nct_id>
  </id_info>
  <brief_title>Biparametric MRI in Prostate Cancer Screening: a Noninferior Randomized Controlled Study</brief_title>
  <official_title>Biparametric MRI in Prostate Cancer Screening: a Noninferior Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai East Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single centre non-inferiority randomized controlled trial in comparison of the&#xD;
      bpMRI between the traditional pathway in prostate cancer screening&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of men with clinically significant cancer</measure>
    <time_frame>Within 1 month after the biopsy</time_frame>
    <description>The presence of a single biopsy core indicating disease of ISUP 2 or more</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of men with clinically insignificant cancer</measure>
    <time_frame>Within 1 month after the biopsy</time_frame>
    <description>The presence of a single biopsy core indicating disease of ISUP 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of men who do not undergo biopsy</measure>
    <time_frame>Within 1 month after the biopsy</time_frame>
    <description>The proportion of men who do not need for further biopsy in this trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of men with adverse events after the intervention</measure>
    <time_frame>Within 1 week after the biopsy</time_frame>
    <description>Any of the adverse events during the trial</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>bpMRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Man receive the bpMRI for Prostate cancer screening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PSA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Man receive the PSA blood test for Prostate cancer screening</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>biparametric MRI (bpMRI)</intervention_name>
    <description>Men go for the mpMRI for PCa screening, those who had a suspicious result will go for the next confirmation test</description>
    <arm_group_label>bpMRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Prostate cancer antigen (PSA)</intervention_name>
    <description>Men go for the PSA test for PCa screening, those who had a suspicious result will go for the next confirmation test</description>
    <arm_group_label>PSA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age between 18 and 80 years old&#xD;
&#xD;
          2. life-expectancy at least 10 years&#xD;
&#xD;
          3. fully understand the clinical trial protocol and sign the informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Already diagnosis with prostate cancer;&#xD;
&#xD;
          2. cannot tolerate prostate biopsy or has contraindication to biopsy;&#xD;
&#xD;
          3. cannot tolerate prostate biopsy or has contraindication to MRI examation;&#xD;
&#xD;
          4. undergo biopsy within 1 year&#xD;
&#xD;
          5. patients judged by the investigator to be unsuitable to participate in the clinical&#xD;
             trial;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haifeng Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital,Tongji University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Biming He</last_name>
    <phone>+8615502139410</phone>
    <email>190589109@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haifeng Wang</last_name>
    <phone>+8613681750891</phone>
    <email>446720864@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai East Hospital, Tongji University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>screen</keyword>
  <keyword>bpMRI</keyword>
  <keyword>PSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Once available, the results of this trial will be disseminated to an international peer-reviewed journal and presentations at international or national academic conferences. The data will be made available upon request to researchers a) who provide a methodologically sound proposal and b) whose proposed use of the data has been approved by an independent ethical review committee</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will become available after publication with no end date</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

